Neutrolis Inc
PrivateLast Round
Series B
Oct 29, 2025
Total Funding Raised
$33.56M
Company Overview
Neutrolis Inc operates in Healthcare & Life Sciences and is based in Cambridge, Massachusetts. Its latest recorded funding round was a VC Round in July 2025.
Neutrolis Inc is a biotechnology company that develops precision therapies for autoimmune and inflammatory diseases by targeting Neutrophil Extracellular Traps (NETs).
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Neutrolis Inc Comparables
Compare Neutrolis Inc with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Ardiyon Bio | 85% | |
| Citryll | 81% | |
| Sonoma Biotherapeutics | 64% |
For institutional investors. Book with your work email.
Neutrolis Inc Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Oct 29, 2025 | ||||
| VC Round | Jul 8, 2025 | ||||
| VC Round | Feb 28, 2025 | ||||
| Series A | Dec 3, 2021 | ||||
| Grant | Aug 3, 2020 | ||||
Accelerator | Nov 28, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Neutrolis Inc Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| U.S. Department of Health and Human Services | Grant |
| NIH RADx | Grant |
| Prefix Capital | VC Round, Series A, Seed |
| PBJ Capital | VC Round, Series A |
| Pfizer | Accelerator |
| Morningside Group | Series A |
| National Institutes of Health (NIH) | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 16, 2026
Monthly visitors increased 46% MoM.
- Apr 15, 2026
Caren Deardorf appointed as Chief Business & Strategy Officer.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventNov 9, 2026
Neutrolis announces that full results from the completed Phase 1a portion of the LIBERATE-I trial are presented as a poster at ACR Convergence 2026, held Nov 6th–11th '26 in Florida.
For institutional investors. Book with your work email.
Neutrolis Inc Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Neutrolis Inc's valuation, stock price, and market status.
Is Neutrolis Inc a public or private company?
Neutrolis Inc is a private company.
What is the current stock price of Neutrolis Inc?
Neutrolis Inc is a private company, so its shares have no public market price. Caplight tracks Neutrolis Inc's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Neutrolis Inc worth (valuation)?
Valuation information for Neutrolis Inc is not publicly available.
Can I buy Neutrolis Inc stock?
Neutrolis Inc shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Neutrolis Inc's last funding round?
Neutrolis Inc's most recent funding round was Series B on October 29, 2025.
Who are the main investors in Neutrolis Inc?
Key investors in Neutrolis Inc include Morningside Group.
Will Neutrolis Inc IPO soon?
No public IPO plans have been announced for Neutrolis Inc.
How can I track Neutrolis Inc secondary market activity?
Caplight tracks bids, offers, and trades in Neutrolis Inc's shares on secondary markets.